EGFR and cancer: By inhibiting cancer cell growth mainly through interfering with signaling pathways, such as the Epidermal growth factor receptor (EGFR)-Mediated Extracellular signal-regulated kinases/Mitogen-activated protein kinases (ERK/MAPK), Wnt/β-catenin or PI3K/AKT/mTOR (partially overlapping with these responsible for proapoptotic, antiangiogenic or antimetastatic potential) natural metaboliteshave the potential to prevent the cancer progression and improve the efficacy of cancer treatments (Cumaoglu et al., 2018; Yang et al., 2021; Kombiyil and Sivasithamparam, 2023).